Drug
:
CPI-0610
Company:
Constellation Pharmaceuticals
Study name
: A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis
Enrolling
: Myelofibrosis patients with a DIPPSS
risk category of intermediate-1 or higher.
To learn more click
here
.